CBIZ (CBZ) Q2 EPS Jumps 64%

CBIZ reported strong Q2 2025 results, with adjusted EPS of $0.95 beating consensus by 13% and rising 63.8% year-over-year, largely due to the Marcum acquisition and effective cost controls. While GAAP revenue increased 62.7% year-over-year to $683.5 million, it missed estimates by 2.6% due to anticipated declines in legacy Marcum capital markets work and soft project-based income. Despite significant margin expansion, integration expenses of $19.2 million in Q2 and the company's focus on reducing acquisition-related leverage remain key areas for investors to monitor, though full-year guidance was maintained.

Analysis

CBIZ's Q2 2025 results present a narrative of successful, large-scale acquisition integration driving significant bottom-line outperformance, albeit with top-line pressures. The company reported adjusted EPS of $0.95, a 63.8% year-over-year increase that surpassed consensus estimates by 13%, primarily due to the accretive impact of the Marcum LLP acquisition and disciplined cost management. This profitability is further evidenced by a 127.9% surge in adjusted EBITDA and a notable expansion in adjusted EBITDA margin to 17.1% from 12.2% in the prior year. However, GAAP revenue, while up 62.7% to $683.5 million, missed analyst forecasts by 2.6%. This shortfall was anticipated by management and attributed to a strategic wind-down of lower-margin legacy Marcum businesses, such as its SPAC practice, alongside broader softness in project-based advisory work. The financial health of the integration is a key focus, with $19.2 million in integration costs incurred in the quarter and a full-year outlook of $75 million. Management has maintained its full-year 2025 guidance, including an adjusted EPS range of $3.60-$3.65, but the wide revenue forecast of $2.8-$2.95 billion signals caution surrounding the 23% of revenue derived from more volatile project work. The balance sheet reflects the acquisition with net debt at approximately $1.51 billion, though management has a clear deleveraging plan to bring leverage below 2.5x by the end of 2026, supported by strong operating cash flow as indicated by the improvement in days sales outstanding (DSO) from 95 to 87 days.

Key Decisions for Investors

• Investors should monitor the execution of the Marcum integration, specifically tracking quarterly integration costs against the full-year $75 million budget and looking for initial signs of the projected $25 million in annual synergies.
• Given the revenue miss, it is crucial to differentiate between the stable, recurring revenue segment (77% of total) and the more volatile project-based work, as persistent softness in the latter could hinder top-line growth despite strong core performance.
• The company's commitment to deleveraging is a key medium-term catalyst; progress toward reducing the debt-to-EBITDA ratio below 2.5x by 2026 should be watched closely as it could de-risk the equity and free up capital for shareholder returns.
• Consider updating valuation models to reflect the maintained full-year adjusted EPS guidance of $3.60-$3.65, weighing the demonstrated margin expansion and profitability against the integration costs and revenue headwinds.